Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Lake Street Capital
Lake Street Capital began coverage of Aligos Therapeutics (NASDAQ:ALGS), assigning a “buy” rating and a $45.00 price target, according to MarketBeat Ratings. Other analysts cited mixed views, with Cantor “overweight” at $20 and Westpark “buy” at $48; MarketBeat shows a $38.50 consensus target. ALGS reported May 7 EPS of -$2.21 vs -$2.29 expected and revenue of $2.83M vs $0.25M.
How this was made
The 30-second read
Why it matters
New initiation (Buy/$45) can attract incremental flows and tighten perceived downside, but the fundamental backdrop remains loss-making with only modestly sized quarterly revenue.
Market read
For traders, the actionable element is the fresh initiation and target, occurring alongside a recent earnings beat that may reinforce near-term sentiment.
What to watch
The article doesn’t add new pipeline readouts or financing terms; for ALGS, those catalysts typically dominate price action over analyst target changes.
Background
The piece is a coverage-initiation note for Aligos Therapeutics, bundled with a recap of recent sell-side ratings and the May 7 earnings print.
Ticker impact
Lake Street initiated coverage with a Buy rating and $45 target, adding fresh sell-side framing for Aligos Therapeutics after its May 7 earnings.
Bias toward short-term upside/volatility as coverage and targets circulate; follow-through likely depends on subsequent pipeline/financing news.
The article provides a new initiation (Lake Street) plus a recent earnings datapoint (EPS beat and revenue above consensus), both of which can move micro-cap biotech sentiment, though no new clinical/contract catalyst is disclosed.
Market effects
Incremental sell-side attention can temporarily lift sentiment across clinical-stage biotech peers, but no sector-wide regulatory/clinical catalyst is cited.
No specific regional linkage beyond US-listed small-cap biotech coverage.
Limited—news is primarily analyst-coverage and company-specific earnings context.
Counterpoint
Despite the EPS and revenue beat, the company still has deeply negative margins and expects further negative EPS, so targets may be more optimistic than fundamentals.
Key entities
- companyAligos Therapeutics
Clinical-stage biopharmaceutical company; subject of the analyst coverage initiation and recent earnings recap.
- analyst_firmLake Street Capital
Initiated coverage with a Buy rating and $45 price target.
- analyst_firmJefferies Financial Group
Raised rating to strong-buy (March 26).
- analyst_firmCantor Fitzgerald
Began coverage with overweight and $20 target (May 21).
